Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide

• Main Authors: Maria Elena Lunati (Author), Vincenzo Cimino (Author), Davide Bernasconi (Author), Alessandra Gandolfi (Author), Paola Silvia Morpurgo (Author), Camilla Tinari (Author), Elisa Lazzaroni (Author), Laura Baruffaldi (Author), Milena Muratori (Author), Laura Montefusco (Author), Ida Pastore (Author), Antonio Rossi (Author), Ivano Giuseppe Franzetti (Author), Fabrizio Muratori (Author), Roberto Manfrini (Author), Olga Eugenia Disoteo (Author), Rosa Terranova (Author), Paolo Desenzani (Author), Angela Girelli (Author), Renata Ghelardi (Author), Francesca D'Addio (Author), Moufida Ben Nasr (Author), Cesare Berra (Author), Franco Folli (Author), Loredana Bucciarelli (Author), Paolo Fiorina (Author)
• Format: Book
• Published: Elsevier, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor and semaglutide, a glucagon-like peptide 1 receptor agonist, have both demonstrated efficacy in glycemic control, reducing blood pressure, body weight, risk of renal and heart failure in type 2 diabetes mellitus. In this observational, real-...